Triazolam
Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.
Clinical data | |
---|---|
Trade names | Halcion |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684004 |
License data | |
Pregnancy category |
|
Routes of administration | Oral (by mouth) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 44% (oral route), 53% (sublingual) |
Metabolism | Liver |
Onset of action | 15–30 minutes |
Elimination half-life | 1.5–5.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.811 |
Chemical and physical data | |
Formula | C17H12Cl2N4 |
Molar mass | 343.21 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Triazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.